The HIV vaccine test has good results – News

In the test performed in humans and monkeys, there was an immunological response. The findings come from a survey conducted by several US institutions

A new candidate for the HIV preventive vaccine had an immune response – it was tolerated and caused a reaction in the body – in humans and in monkeys.

The HIV vaccine test has good preventive results in humans and monkeys

In the case of animals, the immunizing potential also guarantees the blockage of the virus. More than 30 years after the identification of the HIV virus, scientists are still working on the development of new forms of HIV-1. a preventative vaccine that could end the epidemic that infects about 2 million people each year. In this study, a group of scientists evaluated the action of a number of vaccination regimens for HIV prevention in human volunteers in five countries. Meanwhile, another team tested the same vaccine in rhesus monkeys to find out if it would be able to protect animals from infection with the virus.

The results showed that the vaccine induces a robust immune response in humans and monkeys. In addition, the monkeys were partially immunized against HIV infection. "In animals, the vaccine provided about 67% protection against the virus," said study co-ordinator Dan Barouch of the Beth Israel Deaconess Medical Center (USA)

. previously limited to specific regions of the world. The new immunizer is of a type known as mosaic vaccine, which contains different genetic sequences from several different HIV strains. This type of immunization, according to the researcher, aims to provide sufficient protection against different strains of HIV, which are prevalent worldwide.

The trials included trials of five different Ad26 / Env vaccine regimens to badess their safety and tolerability, and the ability to elicit immune responses in 393 healthy adult volunteers. Based on these data, the vaccine has moved to the next phase of clinical trials, with the goal of providing the vaccine to the population of the United States of America and the United States of America.

Next steps

according to Barouch.

The next phase of clinical trials involves the participation of 2,600 South African women who are able to determine if the vaccine is capable of preventing human infection in South Africa. at risk of HIV infection. "Our goal is that the results be ready between 2021 and 2022. This will be only the fifth vaccine concept that will be tested for human efficacy throughout the more than 35-year history of the epidemic." HIV, "said the scientist. Professor at Harvard Medical School (USA)

Barouch says that good results should be interpreted with caution. "The challenges to developing an HIV vaccine are unprecedented and the ability to induce specific immune responses against this virus does not necessarily indicate that the vaccine will protect humans from HIV infection," was -he says. millions of people around the world are living with HIV / AIDS and about 1.8 million new cases are registered each year. "A safe and effective preventive vaccine is urgently needed to reduce the HIV pandemic."

Since the beginning of the epidemic, only four concepts of HIV vaccines have been tested in humans and only one has provided proof of protection efficacy test – gp120, which has has been tested in Thailand and reduces the rate of infection in humans by 31%. However, the effect was considered too low for the vaccine to be used.

The new study was also followed by scientists from the Ragon Institute – HIV Study Center established in 2009 in partnership between Harvard, the Mbadachusetts Institute of Technology (MIT) and Mbadachusetts General Hospital, the US Military HIV Research Program, the National Institute of Allergy and Infectious Diseases, the International AIDS Vaccine Initiative, the Multiple HIV Vaccine Test other partners.

Copyright © 2018 Estadão. All rights reserved